Deconvolution-based dynamic contrast-enhanced MR imaging of breast tumors: correlation of tumor blood flow with human epidermal growth factor receptor 2 status and clinicopathologic findings--preliminary results.

PURPOSE To prospectively determine whether breast carcinomas possess characteristic values of tumor blood flow (TBF) that correlate with pathologic and molecular prognostic markers. MATERIALS AND METHODS The institutional ethics committee approved this study. After informed consent was obtained, 57 women (age range, 31-80 years) with histologically proved breast cancer underwent routine magnetic resonance (MR) mammography, which included a whole-breast dynamic contrast material-enhanced (DCE) sequence. A second contrast material bolus was injected during dynamic single-section turbo field-echo imaging of the section where the lesion was maximally enhanced. The relative signal intensity changes were deconvolved in a pixelwise fashion to yield the TBF. Formalin-fixed paraffin-embedded tumor specimens on slides were evaluated for histologic size and grade, as well as for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) protein. In patients with a HER2 protein score of 2+ or 3+, HER2 gene status was assessed. For all prognostic parameters, the Mann-Whitney U test was used to compare median TBF in the HER2-positive group with that in the HER2-negative group. RESULTS Significantly higher TBF was observed in tumors larger than 2 cm in diameter and in PR-negative and HER2 gene-amplified tumors (P < .05). In the HER2-positive and HER2-negative groups, ER-positive PR-positive tumors had a lower median TBF than did ER-negative PR-negative tumors, and the difference was significant in the HER2-positive group (P < .05). CONCLUSION Pixelwise deconvolution analysis of DCE MR data in patients with breast cancer can provide preoperative information regarding TBF. These results also support the hypothesis that there is increased TBF in HER2-positive tumors.

[1]  S. Edge,et al.  Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. , 1995, Radiology.

[2]  J. Beneke,et al.  HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. , 2002, American journal of clinical pathology.

[3]  N. Goldstein,et al.  Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.

[4]  J. R. Reeves,et al.  Evaluating HER2 amplification and overexpression in breast cancer , 2001, The Journal of pathology.

[5]  M. Beer,et al.  Prebolus quantitative MR heart perfusion imaging , 2004, Magnetic resonance in medicine.

[6]  G. Vogl,et al.  HER2 Is Unlikely to Be Involved in Directly Regulating Angiogenesis in Human Breast Cancer , 2006, Applied immunohistochemistry & molecular morphology : AIMM.

[7]  D. Slamon,et al.  Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Kuhl,et al.  Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? , 1999, Radiology.

[9]  H. Degani,et al.  Magnetic resonance imaging of tumor vasculature , 2003, Thrombosis and Haemostasis.

[10]  R. Kumar,et al.  The role of HER2 in angiogenesis. , 2001, Seminars in oncology.

[11]  Gottfried Konecny,et al.  Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. , 2003, Journal of the National Cancer Institute.

[12]  R Luypaert,et al.  Quantification of perfusion and permeability in breast tumors with a deconvolution‐based analysis of second‐bolus T1‐DCE data , 2007, Journal of magnetic resonance imaging : JMRI.

[13]  R Kozak,et al.  CT assessment of cerebral perfusion: experimental validation and initial clinical experience. , 1999, Radiology.

[14]  James H Thrall,et al.  Imaging angiogenesis: applications and potential for drug development. , 2005, Journal of the National Cancer Institute.

[15]  N. Tunçbilek,et al.  Dynamic magnetic resonance imaging in determining histopathological prognostic factors of invasive breast cancers. , 2005, European journal of radiology.

[16]  Orhan Nalcioglu,et al.  Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer , 2003, Journal of magnetic resonance imaging : JMRI.

[17]  J. Folkman,et al.  The role of angiogenesis in tumor growth. , 1992, Seminars in cancer biology.

[18]  S. Sourbron,et al.  Deconvolution of dynamic contrast‐enhanced MRI data by linear inversion: Choice of the regularization parameter , 2004, Magnetic resonance in medicine.

[19]  A. Schauer,et al.  Prognostic value of contrast-enhanced MR mammography in patients with breast cancer , 1997, European Radiology.

[20]  I. Bauerfeind,et al.  Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients , 2004, Clinical Cancer Research.

[21]  Qiqin Yin-Goen,et al.  Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression , 2005, Modern Pathology.

[22]  P. Devroey,et al.  Human endometrial maturation is markedly improved after luteal supplementation of gonadotrophin-releasing hormone analogue/human menopausal gonadotrophin stimulated cycles. , 1994, Human reproduction.

[23]  L. Holmberg,et al.  Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Geyer,et al.  Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma , 2005, Cancer.

[25]  Pamela F. Jones,et al.  Angiogenesis in breast cancer: how should we measure this? (Review). , 2005, Oncology reports.

[26]  A. Harris,et al.  Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer , 1992, The Lancet.

[27]  A Horsman,et al.  Prediction of axillary lymph node status in invasive breast cancer with dynamic contrast-enhanced MR imaging. , 1997, Radiology.

[28]  G Brix,et al.  Pathophysiologic basis of contrast enhancement in breast tumors , 1999, Journal of magnetic resonance imaging : JMRI.

[29]  M. Dewhirst,et al.  HER-2 Gene Amplification Correlates with Higher Levels of Angiogenesis and Lower Levels of Hypoxia in Primary Breast Tumors , 2004, Clinical Cancer Research.

[30]  A. Djamali,et al.  Nephrogenic systemic fibrosis: risk factors and incidence estimation. , 2007, Radiology.

[31]  I. Gribbestad,et al.  Comparative signal intensity measurements in dynamic gadolinium‐enhanced MR mammography , 1994, Journal of magnetic resonance imaging : JMRI.

[32]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[33]  S Sourbron,et al.  Pixel-by-pixel deconvolution of bolus-tracking data: optimization and implementation , 2007, Physics in medicine and biology.

[34]  Tibor Tot,et al.  Invasive breast cancer: correlation of dynamic MR features with prognostic factors , 2003, European Radiology.

[35]  M. Oudkerk,et al.  Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine. , 2003, AJR. American journal of roentgenology.

[36]  Masaki Kakimoto,et al.  Correlation among intratumoral blood flow in breast cancer, clinicopathological findings and Nottingham Prognostic Index. , 2003, Japanese journal of clinical oncology.

[37]  P J Drew,et al.  Microvessel density in invasive breast cancer assessed by dynamic gd‐dtpa enhanced MRI , 1997 .

[38]  M. Tonato,et al.  Evaluation of the Prognostic Role of Vascular Endothelial Growth Factor and Microvessel Density in Stages I and II Breast Cancer Patients , 2003, Breast Cancer Research and Treatment.

[39]  R Luypaert,et al.  Quantification of renal perfusion and function on a voxel‐by‐voxel basis: A feasibility study , 2005, Magnetic resonance in medicine.

[40]  H. Lehr,et al.  Dynamic MR imaging of breast lesions: correlation with microvessel distribution pattern and histologic characteristics of prognosis. , 2006, Radiology.

[41]  S. Mousa,et al.  Estrogen Receptor-α in the Inhibition of Cancer Growth and Angiogenesis , 2000 .

[42]  R. Lucht,et al.  Microcirculation and microvasculature in breast tumors: Pharmacokinetic analysis of dynamic MR image series , 2004, Magnetic resonance in medicine.

[43]  S. Hirohashi,et al.  correlation between histologic grade of malignancy and copy number of c‐erbb‐2 gene in breast carcinoma. A retrospective analysis of 176 cases , 1990, Cancer.